The Pharmaceuticals Benefits Advisory Committee (PBAC) has recommended the listing of quadrivalent influenza vaccine (QIV, Vaxigrip TetraTM) on the National Immunisation Program (NIP) for the prevention of seasonal influenza in children aged 6 months to <5 years as well as for individuals who are currently eligible for seasonal influenza vaccination through the NIP in 2020.